Lipid-lowering drugs as primary prevention in general practice: Do patients reach guideline goals and continue treatment? ADDITION Denmark

Author： Graversen Lise Christensen Bo Borch-Johnsen Knut Lauritzen Torsten Sandbaek Annelli

Publisher： Informa Healthcare

ISSN： 0281-3432

Source： Scandinavian Journal of Primary Health Care, Vol.29, Iss.4, 2011-12, pp. : 216-221

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cancer mortality according to lipid-lowering drugs and lipoproteins in a general population

By Bérard E. Bongard V. Dallongeville J. Arveiler D. Ruidavets J.B. Ferrières J.

Current Medical Research and Opinion, Vol. 27, Iss. 10, 2011-10 ,pp. : 1963-1971

Informa Healthcare

Access to resources Recommend Favorite

Why do sales of lipid-lowering drugs vary between counties in Norway?

By Hartz Ingeborg Njølstad Inger Furu Kari Skurtveit Svetlana Elise Eggen Anne

Scandinavian Journal of Primary Health Care, Vol. 24, Iss. 2, 2006-06 ,pp. : 115-121

Informa Healthcare

Access to resources Recommend Favorite

Lipid-Lowering Drugs: Are Adverse Effects Predictable and Reversible?

Cardiology, Vol. 97, Iss. 3, 2002-06 ,pp. : 115-121

Karger

Access to resources Recommend Favorite

The use of lipid-lowering drugs across ethnic groups in the secondary prevention of ischaemic heart disease: analysis of cross-sectional surveys in England

By Gill Paramjit S Quirke Terry P Mant Jonathan W Allan Teresa F

British Journal of General Practice, Vol. 54, Iss. 503, 2004-06 ,pp. : 442-443

Royal College of General Practitioners

Access to resources Recommend Favorite

Do Lipid Lowering Drugs Reduce the Risk of Coronary Heart Disease?

By Pritzker L. B.

Critical Reviews in Clinical Laboratory Sciences, Vol. 35, Iss. 6, 1998-12 ,pp. : 603-621

Informa Healthcare

Access to resources Recommend Favorite